Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NovAliX Appoints CSO

Published: Wednesday, October 17, 2012
Last Updated: Wednesday, October 17, 2012
Bookmark and Share
Appointment of Dr Luc Van Hijfte as CSO drug discovery.

NovAliX has announced that it has appointed pharma research executive Dr Luc Van Hijfte as CSO Drug Discovery.

Dr. Van Hijfte brings a wealth of experience in pharmaceutical research with over 25 years spent in drug discovery.

He joined from Janssen, a J&J company, where he served as Head of Medicinal Chemistry EU with responsibility over European based chemical sciences and ADMET.

During this tenure, that included responsibility as site head of the Janssen-Cilag Research Center in Val de Reuil, Dr Van Hijfte has been privileged to contribute to several successful projects with numerous programs entering into clinical development in the areas of Neurosciences, Oncology and Infectious Diseases, with compounds up to phase III level, the most advanced being the anti-tuberculosis compound TMC 207 currently being reviewed by the FDA for market authorization.

Prior to that Dr Van Hijfte had responsibilities at Hoechst Marion Roussel, subsequently at Sanofi as Head of chemistry of the Strasbourg research center.

Luc Van Hijfte earned his PhD in organic synthetic chemistry from the University of Gent under the supervision of Pr. M. Vandewalle, and has completed a post-doctoral training at the University of California, Santa Barbara, in the laboratory of Pr. R.D. Little.

Dr Van Hijfte, who is sharing the vision of the company founders, believing in the relevance of biophysical sciences for drug discovery commented, "I have been impressed by the scope and scale of the biophysical technologies NovAliX has assembled. That was a compelling argument to join the company and have the opportunity to run fragment-based discovery programs".

Both, Denis Zeyer, CEO, and Jean-Paul Renaud, CSO Science & Technology, and founding members of the company are enthusiastic about that addition to the team. "This is a defining moment for our company. Since inception, we have been concentrating on the development of our scientific capabilities in chemistry and biophysics, using a combination of internal technology developments and external sourcing including corporate acquisitions and academic collaborations. With Luc Van Hijfte now joining the team, we add significant pharmaceutical research leadership to our small molecule discovery capabilities".


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FEI and NovAliX Partner
Company has announced partnership with FEI to provide electron microscopy-based structural biology services for the pharmaceutical and biotech industry.
Tuesday, March 22, 2016
NovAliX/Kyowa Hakko Kirin Alliance Commence Fragment-Based Drug Discovery Project
The companies will commence research against a new clinically significant target involving the discovery of novel small molecules that modulate protein-protein interaction.
Monday, November 18, 2013
NovAliX and Inventiva Form a Strategic Alliance on Nuclear Receptors
Inventiva and NovAliX announced that they have entered into a strategic alliance dedicated to the discovery of clinical candidates, targeting nuclear receptors.
Tuesday, April 09, 2013
NovAliX Partners with Kyowa Hakko Kirin
NovAliX SAS announced today that it has entered into a fragment-based drug discovery alliance with Kyowa Hakko Kirin Co., Ltd., Japan.
Thursday, January 17, 2013
NovAliX Enters into Alliance with Kyowa Hakko Kirin
Companies will collaborate to develop novel drug candidates against protein-protein interaction targets.
Monday, January 14, 2013
NovAliX and Servier Collaborate in Early Discovery Research Program
Under the terms of Graffinity agreement, a NovAliX subsidiary, will be responsible for the discovery of specific small molecule lead candidates for a novel exploratory target chosen by Servier.
Wednesday, October 10, 2012
NovAliX Enters into Multi-Target Integrated Drug Discovery Collaboration with Teijin Pharma
The companies will develop novel drug candidates against multiple targets across different therapeutic areas.
Thursday, January 12, 2012
NovAliX to Collaborate with the Fondation Jérôme Lejeune on Down Syndrome (Trisomy 21)
NovAliX will use its expertise and capabilities in medicinal chemistry and structural biology to develop small molecule lead candidates targeting the CBS.
Friday, September 16, 2011
NovAliX and Galapagos Collaborate in Osteoarthritis Discovery Research Program
NovAliX will be responsible for the discovery of specific small molecule lead candidates for a novel, validated osteoarthritis target chosen by Galapagos.
Monday, August 29, 2011
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!